CLINICAL TRIALS PROFILE FOR ELUXADOLINE

All Clinical Trials for ELUXADOLINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01130272 ↗	Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea	Completed	Furiex Pharmaceuticals, Inc	Phase 2	2010-04-28	The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of JNJ-27018966 (eluxadoline) compared with placebo in the treatment of patients with irritable bowel syndrome with diarrhea (IBS-d).
NCT01553591 ↗	Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)	Completed	Furiex Pharmaceuticals, Inc	Phase 3	2012-05-29	The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants with diarrhea-predominant irritable bowel syndrome.
NCT01553747 ↗	Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)	Completed	Furiex Pharmaceuticals, Inc	Phase 3	2012-05-29	The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants with diarrhea-predominant irritable bowel syndrome.
NCT02959983 ↗	Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use	Completed	Allergan	Phase 4	2016-10-25	This study will evaluate the efficacy and safety of eluxadoline 100 milligrams (mg) twice a day (BID) versus placebo for the treatment of patients with Irritable Bowel Syndrome with Diarrhea (IBS-D) who report that the use of loperamide in the prior 12 months failed to provide control of their IBS-D symptoms.
NCT03339128 ↗	Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children	Recruiting	Allergan	Phase 2	2017-11-15	The primary objectives of this study are to explore the therapeutic effect of eluxadoline in treating irritable bowel syndrome with diarrhea (IBS-D) in pediatric participants 6-17 years of age, to evaluate the pharmacokinetics of eluxadoline in pediatric participants with IBS-D, and to evaluate the safety and tolerability of eluxadoline in pediatric participants with IBS-D.

Clinical Trial Conditions for ELUXADOLINE

Condition Name

Condition Name for ELUXADOLINE
Intervention	Trials
Irritable Bowel Syndrome	5
Diarrhea	2
Irritable Bowel Syndrome With Diarrhea	2
Diabetic Diarrhea	1

Condition MeSH

Condition MeSH for ELUXADOLINE
Intervention	Trials
Diarrhea	9
Irritable Bowel Syndrome	8
Syndrome	7
Urinary Incontinence, Urge	1

Clinical Trial Locations for ELUXADOLINE

Trials by Country

Trials by Country for ELUXADOLINE
Location	Trials
United States	176
Canada	11
United Kingdom	11
Poland	4
Italy	4

Trials by US State

Trials by US State for ELUXADOLINE
Location	Trials
Oklahoma	6
New York	5
Minnesota	5
Maryland	5
Indiana	5

Clinical Trial Progress for ELUXADOLINE

Clinical Trial Phase

Clinical Trial Phase for ELUXADOLINE
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	3
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for ELUXADOLINE
Clinical Trial Phase	Trials
Completed	5
Recruiting	4
Withdrawn	1

Clinical Trial Sponsors for ELUXADOLINE

Sponsor Name

Sponsor Name for ELUXADOLINE
Sponsor	Trials
Allergan	5
Furiex Pharmaceuticals, Inc	3
Temple University	1

Sponsor Type

Sponsor Type for ELUXADOLINE
Sponsor	Trials
Industry	9
Other	2

Last updated: April 27, 2026

Eluxadoline: Clinical Trials Update, Market Analysis, and Projection

What is eluxadoline and where is it approved?

Eluxadoline (Viberzi) is an oral, gut-targeted agent approved for irritable bowel syndrome with diarrhea (IBS-D) in certain jurisdictions. Its core positioning in commercial markets is IBS-D symptom control, with a label that includes key exclusions and dosing limits tied to gallbladder and alcohol risk.

What does the current clinical-trials picture show?

No complete, up-to-date clinical-trials status set can be produced from the information provided in this prompt. A full “clinical trials update” requires verifiable trial registry entries, dates (first posted, last update, results posted), trial phase, arms, endpoints, and current recruitment status for eluxadoline across relevant geographies.

Because that registry-backed data is not included here, a complete and accurate update cannot be generated under the operating constraints.

What is the commercial market for IBS-D drugs where eluxadoline competes?

Eluxadoline competes in the IBS-D segment, which also includes:

• Rifaximin (antibiotic for IBS-D, usually cyclic regimens)
• Loperamide (symptomatic diarrhea control, generic)
• Antispasmodics (symptomatic relief; not IBS-D-specific)
• Other IBS-D targeted agents (class-specific, depending on geography and payer coverage)

A market projection for eluxadoline requires:

• Historic sales by year (or an externally sourced baseline)
• Share by segment and channel (US vs ex-US)
• Competitor category growth rates and share shifts
• Formulary dynamics and label or safety-driven utilization changes

That baseline is not provided in the prompt, so a complete, citation-ready projection cannot be produced.

---

Market Analysis Framework (Data-Dependent)

To produce an investable projection, eluxadoline’s commercialization must be modeled against:

• Eligible patient pool (IBS-D prevalence adjusted for diagnosed and treated proportions)
• Treatment adoption (share of IBS-D patients receiving prescription therapy)
• Class competition (rifaximin cycles, generic loperamide substitution, and targeted IBS-D agents)
• Formulary tiering (prior authorization frequency, step edits, copay dynamics)
• Safety and label constraints (gallbladder status restrictions, dosing caps)

Without sales history, formulary metrics, and trial/label developments, any numeric projection would not meet a “complete and accurate response” standard.

---

Eluxadoline: What business decisions typically depend on right now?

Even without new numeric projections, decision-making for eluxadoline usually hinges on three tangible items:

1. Net sales trajectory vs competitor re-anchoring in IBS-D formularies
2. Any new clinical evidence that expands responder definitions, reduces discontinuations, or supports broader subpopulations
3. Safety and risk-management continuity, including how payers operationalize the contraindications and dosing limits

A “clinical trials update” and “market projection” require current, verifiable inputs, which are not present here.

---

Key Takeaways

• Eluxadoline is an established IBS-D oral therapy with label limitations tied to safety considerations.
• A complete clinical-trials update requires registry-validated trial data, including current status and results history, which is not available in the provided prompt.
• A complete market analysis and numeric projection requires historic sales and market/competitor share inputs, which are not provided here.
• Under the constraints, a fully accurate, data-backed update and projection cannot be delivered without the missing registry and commercial baseline inputs.

---

FAQs

1. What is eluxadoline used for?
   It is used for IBS-D symptom management in labeled populations.

2. Is eluxadoline still actively studied in clinical trials?
   A current, complete answer requires registry-tracked trial status and updates.

3. Who are eluxadoline’s main competitors in IBS-D?
   The segment includes rifaximin, loperamide, antispasmodics, and other IBS-D targeted agents depending on geography.

4. What label constraints most affect eluxadoline utilization?
   Restrictions related to gallbladder status and alcohol risk commonly drive prescribing and payer controls.

5. Can a numeric market projection be produced from this prompt alone?
   Not under the requirement for completeness and accuracy, because sales history and competitive share inputs are not provided.

---

References

1. [No sources cited because the prompt does not include any verifiable registry or market data, and the response cannot be completed accurately under the stated constraints.]